Groundbreaking Research Reveals New Avenues for Blood Cancer Treatment

Strategic Insights -

Australian researchers at the Olivia Newton-John Cancer Research Institute (ONJCRI) and WEHI have made a significant discovery in the field of blood cancer research. By studying a single mutation in the DNA sequence for a methylation enzyme, they have identified a potential target for effective blood cancer treatment. This mutation, in the DNA methyltransferase 3A (DNMT3A) gene, is found in approximately 20-25% of adults with acute myeloid leukaemia (AML). The researchers used pre-clinical models to demonstrate that this mutation hinders the enzyme's ability to conduct the methylation process, leading to a cascade of cellular signalling pathways going wrong and potentially causing cancer.

Key Takeaways:

  • A single mutation in the DNA sequence for a methylation enzyme, DNMT3A, dysregulates key tumour-suppressing pathways, opening up new avenues for blood cancer treatment.
  • The mutation is found in approximately 20-25% of adults with acute myeloid leukaemia (AML).
  • Researchers used pre-clinical models to demonstrate that the mutation hinders the enzyme's ability to conduct the methylation process, leading to a cascade of cellular signalling pathways going wrong.
  • The p53 tumour-suppressor signalling pathway is silenced in cells with DNMT3A mutations, increasing the likelihood that these cells will accumulate additional cancer-causing mutations.
  • CRISPR-Cas technology was used to introduce the specific DNA mutation in DNMT3A, confirming the link between the mutation and cancer development.
  • Not all individuals living with this mutation will go on to develop cancer, with 10-20% of people over the age of 60 or 70 having the mutation without developing cancer.
  • These insights could offer new avenues to treat DNMT3A-mutant cancers, which are currently challenging to treat and have no targeted therapies.

Statistics:

  • Approximately 20-25% of adults with acute myeloid leukaemia (AML) have the DNMT3A mutation.
  • Nearly 150,000 people were living with AML worldwide in 2021.
  • 10-20% of people over the age of 60 or 70 have the DNMT3A mutation without developing cancer.

Sources:

  • VerticalNews Health
  • EMBO Reports
  • NHMRC (National Health and Medical Research Council)
  • Australian Rotary Health District 9650
  • The Walter and Eliza Hall Institute
  • WEHI (Walter and Eliza Hall Institute of Medical Research)
  • Phenomics Australia
  • National Collaborative Research Infrastructure Strategy (NCRIS) program
  • Victorian State Government